The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

ioversol     N,N'-bis(2,3- dihydroxypropyl)-5-(2...

Synonyms: Optiray, Ioversolum, Optiray 160, Optiray 240, Optiray 300, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of ioversol


High impact information on ioversol

  • Because of the significant first-pass myocardial retention of ioversol, both mean myocardial appearance time and intramyocardial blood volume were consistently overestimated [6].
  • We tested this assumption by comparing a conventional nonionic contrast agent (ioversol) to a particulate emulsion (ethiodol) that remained in the vascular space in closed-chest dogs during pharmacological vasodilation [6].
  • In mice with unilateral renal occlusion, ioversol increased urinary excretion of N-acetyl-beta-d-glucosaminidase with concomitant decreases in Bcl-2 mRNA, increases in Bax mRNA, activation of caspase-3, and induction of apoptosis in tubular and interstitial cells [7].
  • Ioversol, a radiocontrast medium, caused cell injury accompanied by decreases in Bcl-2, increases in Bax, and caspase activation in LLC-PK1 cells [7].
  • Hexabrix and Optiray induced histamine and tryptase release from human lung mast cells, but not from human skin mast cells [8].

Chemical compound and disease context of ioversol


Biological context of ioversol

  • RESULTS: Beraprost sodium (10 to 1000 nmol/L) attenuated concentration dependently the ioversol-induced decrease in cell viability, in which the protective effect of beraprost sodium was dependent on the elevation of cellular cAMP content [11].
  • METHODS: Isolated mouse proximal tubule segments (PTS), or cultured proximal tubule (HK-2) cells, were subjected to radiocontrast media (RCM) (Ioversol, Optiray 320) exposure, followed by assessments of cellular viability [% lactate dehydrogenase (LDH) release, tetrazolium dye (MTT), uptake] and lipid peroxidation [12].
  • Safety and pharmacokinetics of ioversol in healthy volunteers [13].
  • Reproductive, developmental, and genetic toxicology of ioversol [2].
  • The median lethal dose (LD50) of ioversol administered intravenously to mice, rats, rabbits, and dogs was more than 12 g I/kg, which exceeds the maximal anticipated clinical dose by at least tenfold [14].

Anatomical context of ioversol

  • Induction of micronuclei in lymphocytes of patients undergoing excretory urography with ioversol [15].
  • Recovery of ioversol in urine and feces averaged 86% to 88% of the administered dose, of which all but a few percent was recovered in urine [16].
  • METHODS: Preoperatively, we marked the visceral pleura near the pulmonary nodules with dye, simultaneously injected contrast media (1 water-soluble Optiray [Mallinckrodt Medical Inc, Quebec, Canada], 18 barium sulfate, 11 Lipiodol [Laboratoire Guerbet, Aulnay-sous-Bois, France]) into or around the nodule under computed tomography (CT) guidance [17].
  • RATIONALE AND OBJECTIVES: Enhancement characteristics of a nonionic, dimeric, isotonic contrast medium (iodixanol [Visipaque]) were compared with a nonionic, monomeric contrast medium (ioversol [Optiray]) of the same iodine concentration in spiral computed tomography angiography (CTA) of the abdominal aorta [18].
  • In comparison with iothalamate, ioversol had a greatly reduced propensity to stimulate the release of endothelin, from cultured cells and when injected into anesthetized rats [19].

Associations of ioversol with other chemical compounds


Gene context of ioversol

  • FB(1) reversed ioversol-induced decrease in the immunoreactivities of pAkt and pCREB, reduction in Bcl-2 expression and caspase-3 activation [24].
  • Diatrizoate, ioxaglate, and ioversol inhibited plasminogen binding to plasma clots by 51+/-4% (p<0.001), 30.1+/-4% (p<0.01), and 19.4+/-7% (p=0.07), respectively [25].
  • Ioversol enhanced the activities of caspase-3 and -9, but to a lesser extent, caspase-8 [26].
  • The cell damage induced by a non-ionic contrast medium ioversol was inhibited by specific inhibitors for caspase-3 and -9 but not caspase-8 [26].
  • The effects of the nonionic, low osmolar agent, ioversol, on endothelin release and renal function are investigated [19].

Analytical, diagnostic and therapeutic context of ioversol


  1. Contrast medium-induced pulmonary edema is aggravated by silicone contamination in rats. Sendo, T., Hirakawa, M., Fujie, K., Kataoka, Y., Oishi, R. Radiology. (1999) [Pubmed]
  2. Reproductive, developmental, and genetic toxicology of ioversol. Ralston, W.H., Robbins, M.S., James, P. Investigative radiology. (1989) [Pubmed]
  3. The effect of sodium on the fibrillatory potential of ioversol. Ralston, W.H., Robbins, M.S., Mosier, L.D., Barco, S.J., Adams, M.D., Hopkins, R.M. Investigative radiology. (1988) [Pubmed]
  4. Hypersensitivity reaction to ioversol. Alvarez-Fernández, J.A., Valero, A.M., Pulido, Z., de la Hoz, B., Cuevas, M., Sánchez-Cano, M. Allergy (2000) [Pubmed]
  5. Ioversol. Double-blind study of a new low osmolar contrast agent for peripheral and visceral arteriography. Grassi, C.J., Bettmann, M.A., Finkelstein, J., Reagan, K. Investigative radiology. (1989) [Pubmed]
  6. First-pass entry of nonionic contrast agent into the myocardial extravascular space. Effects on radiographic estimates of transit time and blood volume. Canty, J.M., Judd, R.M., Brody, A.S., Klocke, F.J. Circulation (1991) [Pubmed]
  7. A prostacyclin analog prevents radiocontrast nephropathy via phosphorylation of cyclic AMP response element binding protein. Yano, T., Itoh, Y., Kubota, T., Sendo, T., Koyama, T., Fujita, T., Saeki, K., Yuo, A., Oishi, R. Am. J. Pathol. (2005) [Pubmed]
  8. Human basophil/mast cell releasability. XI. Heterogeneity of the effects of contrast media on mediator release. Stellato, C., de Crescenzo, G., Patella, V., Mastronardi, P., Mazzarella, B., Marone, G. J. Allergy Clin. Immunol. (1996) [Pubmed]
  9. The effect of sodium on the fibrillatory propensity of nonionic contrast media. Piao, Z.E., Murdock, D.K., Hwang, M.H., Raymond, R.M., Scanlon, P.J. Investigative radiology. (1987) [Pubmed]
  10. Cardiac and hemodynamic tolerability of iopromide with or without sodium or iloprost and of ioversol in the anesthetized rat. Krause, W., Muschick, P., Wehrmann, D. Investigative radiology. (1994) [Pubmed]
  11. A prostacyclin analog beraprost sodium attenuates radiocontrast media-induced LLC-PK1 cells injury. Yano, T., Itoh, Y., Kubota, T., Sendo, T., Oishi, R. Kidney Int. (2004) [Pubmed]
  12. Radiographic contrast media-induced tubular injury: evaluation of oxidant stress and plasma membrane integrity. Zager, R.A., Johnson, A.C., Hanson, S.Y. Kidney Int. (2003) [Pubmed]
  13. Safety and pharmacokinetics of ioversol in healthy volunteers. Wilkins, R.A., Whittington, J.R., Brigden, G.S., Lahiri, A., Heber, M.E., Hughes, L.O. Investigative radiology. (1989) [Pubmed]
  14. Acute and subacute toxicity studies of ioversol in experimental animals. Ralston, W.H., Robbins, M.S., Coveney, J., Blair, M. Investigative radiology. (1989) [Pubmed]
  15. Induction of micronuclei in lymphocytes of patients undergoing excretory urography with ioversol. Cochran, S.T., Norman, A. Investigative radiology. (1994) [Pubmed]
  16. Biodistribution and excretion of 125I ioversol in conscious dogs. Coveney, J.R., Robbins, M.S. Investigative radiology. (1989) [Pubmed]
  17. Fluoroscopy-aided thoracoscopic resection of pulmonary nodule localized with contrast media. Moon, S.W., Wang, Y.P., Jo, K.H., Kwack, M.S., Kim, S.W., Kwon, O.K., Jang, H.S. Ann. Thorac. Surg. (1999) [Pubmed]
  18. Spiral CT angiography of the abdominal aorta. Comparison of iodixanol and ioversol. Fischbach, R., Landwehr, P., Svaland, M., Pape, H.G., Brochhagen, H.G., Kampenes, V.B., Heindel, W., Lackner, K. Investigative radiology. (1999) [Pubmed]
  19. Effects of ioversol versus iothalamate on endothelin release and radiocontrast nephropathy. Heyman, S.N., Clark, B.A., Cantley, L., Spokes, K., Rosen, S., Brezis, M., Epstein, F.H. Investigative radiology. (1993) [Pubmed]
  20. Thrombin generation in nonclottable mixtures of blood and nonionic contrast agents. Kopko, P.M., Smith, D.C., Bull, B.S. Radiology. (1990) [Pubmed]
  21. Gadolinium as a CT contrast agent: assessment in a porcine model. Gierada, D.S., Bae, K.T. Radiology. (1999) [Pubmed]
  22. Hemodynamic and electrocardiographic effects of ioversol during cardiac angiography. Comparison with iopamidol and diatrizoate. Hirshfeld, J.W., Wieland, J., Davis, C.A., Giles, B.D., Passione, D., Ray, M.B., Ripley, N.S. Investigative radiology. (1989) [Pubmed]
  23. A double-blind study comparing the safety, tolerability, and efficacy of ioversol 320 and iopamidol-300 in cerebral angiography. Ringel, K., Kuehn, J. Investigative radiology. (1989) [Pubmed]
  24. Involvement of de novo ceramide synthesis in radiocontrast-induced renal tubular cell injury. Itoh, Y., Yano, T., Sendo, T., Sueyasu, M., Hirano, K., Kanaide, H., Oishi, R. Kidney Int. (2006) [Pubmed]
  25. An analysis of mechanisms underlying the antifibrinolytic properties of radiographic contrast agents. Farrehi, P.M., Zhu, Y., Fay, W.P. J. Thromb. Thrombolysis (2001) [Pubmed]
  26. Cyclic AMP reverses radiocontrast media-induced apoptosis in LLC-PK1 cells by activating A kinase/PI3 kinase. Yano, T., Itoh, Y., Sendo, T., Kubota, T., Oishi, R. Kidney Int. (2003) [Pubmed]
  27. Pancreatic arterial anatomy: depiction with dual-phase helical CT. Chong, M., Freeny, P.C., Schmiedl, U.P. Radiology. (1998) [Pubmed]
  28. Double-blind study of a new nonionic contrast agent for cardiac angiography. Reagan, K., Bettman, M.A., Finkelstein, J., Ganz, P., Grassi, C.J. Radiology. (1988) [Pubmed]
  29. Clinical summary of initial intravenous administration of ioversol. McClennan, B.L. Investigative radiology. (1989) [Pubmed]
  30. Clinical profile of ioversol. A metaanalysis of 57 randomized, double-blind clinical trials. Floriani, I., Ciceri, M., Torri, V., Tinazzi, A., Jahn, H., Noseda, A. Investigative radiology. (1996) [Pubmed]
WikiGenes - Universities